Novo Nordisk says new data for Ryzodeg shows positive results for type 2 diabetes
Danish insulin giant Novo Nordisk (NOV: N) has said a new analysis showed Ryzodeg (insulin degludec/insulin aspart) achieved successful glycemic control with significantly lower rates of hypoglycemia and nocturnal hypoglycaemia in patients with type 2 diabetes versus BIAsp 30 and/or a basal-bolus regimen of insulin degludec and insulin aspart.
Helena Rodbard, presenting author of the analyses, said: “Managing hypoglycemia while also achieving optimal glycemic control are important considerations when selecting a treatment regimen. These findings are especially relevant in the era of personalized medicine, and provide valuable assistance to the clinical use of Ryzodeg in patients with type 2 diabetes.”
The findings were presented today at the 23rd World Diabetes Congress of the International Diabetes Federation (IDF).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze